MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Takes Position in Kenvue Inc. (NYSE:KVUE)

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH bought a new stake in shares of Kenvue Inc. (NYSE:KVUE) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,481,177 shares of the company’s stock, valued at approximately $53,246,000. Kenvue accounts for about 1.9% of MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s portfolio, making the stock its 16th largest holding. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH owned about 0.13% of Kenvue at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Planned Solutions Inc. purchased a new stake in shares of Kenvue during the 4th quarter valued at approximately $27,000. Mather Group LLC. purchased a new stake in Kenvue in the 1st quarter worth approximately $28,000. Pacific Capital Wealth Advisors Inc. purchased a new stake in Kenvue in the 4th quarter worth approximately $28,000. CVA Family Office LLC purchased a new stake in Kenvue in the 4th quarter worth approximately $32,000. Finally, Pinnacle Bancorp Inc. lifted its stake in Kenvue by 51.3% in the 4th quarter. Pinnacle Bancorp Inc. now owns 1,552 shares of the company’s stock worth $33,000 after purchasing an additional 526 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Price Performance

KVUE stock traded up $0.29 during trading on Tuesday, hitting $18.24. 14,781,322 shares of the company’s stock traded hands, compared to its average volume of 19,578,275. The business has a fifty day simple moving average of $19.16 and a 200 day simple moving average of $19.95. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.99. The stock has a market capitalization of $34.93 billion, a price-to-earnings ratio of 23.01, a P/E/G ratio of 1.93 and a beta of 1.41. Kenvue Inc. has a 52 week low of $17.75 and a 52 week high of $26.60.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.25 by $0.03. The business had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $3.79 billion. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. The firm’s revenue for the quarter was down 24.9% on a year-over-year basis. As a group, research analysts expect that Kenvue Inc. will post 1.17 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Tuesday, May 7th. This represents a $0.80 annualized dividend and a dividend yield of 4.39%. Kenvue’s dividend payout ratio (DPR) is presently 102.56%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on KVUE shares. Sanford C. Bernstein started coverage on shares of Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price objective on the stock. William Blair assumed coverage on shares of Kenvue in a report on Wednesday, April 3rd. They issued a “market perform” rating on the stock. Citigroup reaffirmed a “neutral” rating and set a $21.00 target price on shares of Kenvue in a research note on Tuesday, May 28th. Finally, HSBC lifted their target price on shares of Kenvue from $20.00 to $21.00 and gave the company a “hold” rating in a research note on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Kenvue has an average rating of “Hold” and a consensus target price of $23.09.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.